Table 3.
IMTs used during 1 year of follow-up from the SSc diagnosis index date
| Type of treatmenta | Patients who received IMTs, n (%) |
|---|---|
| First IMT | N = 2404 |
| Hydroxychloroquine | 1054 (43.8) |
| Methotrexate | 507 (21.1) |
| Mycophenolate mofetil | 422 (17.6) |
| Azathioprine | 165 (6.9) |
| Cyclosporine | 156 (6.5) |
| Biologicsb | 71 (3.0) |
| Leflunomide | 53 (2.2) |
| Cyclophosphamide | 51 (2.1) |
| Penicillamine | 43 (1.8) |
| Sulfasalazine | 22 (0.9) |
| Chloroquine | 11 (0.5) |
| Quinacrine | 2 (0.1) |
| Tofacitinib | 1 (0.04) |
| Switch to second IMTa | N = 460 |
| Methotrexate | 106 (23.0) |
| Mycophenolate mofetil | 105 (22.8) |
| Hydroxychloroquine | 98 (21.3) |
| Biologicsb | 32 (7.0) |
| Leflunomide | 23 (5.0) |
| Cyclophosphamide | 12 (2.6) |
| Other IMTsc | 103 (22.4) |
Data include all patients who received at least one type of treatment
IMT immunomodulatory therapy, SSc systemic sclerosis
aAt least this type of treatment was received
bIncluded the biologics abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, and the targeted synthetic DMARD tofacitinib
cOther IMTs included azathioprine, chloroquine, cyclosporine, penicillamine, quinacrine, and sulfasalazine